Bulletin from the extraordinary general meeting of Lipidor AB (publ)
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Lipidor AB (publ) (“Lipidor” or the “Company”) held an extraordinary general meeting (the “EGM”) on 17 January 2023 in Stockholm. The EGM resolved to approve that the Company transfer shares in the subsidiary Emollivet AB to two major shareholders in Lipidor.
Transfer of shares in the subsidiary Emollivet
The EGM resolved, in accordance with the Board of Directors’ proposal, to approve that the Company transfers shares in the subsidiary Emollivet AB (“Emollivet”) to two of Lipidors major shareholders Cerbios-Pharma SA (“Cerbios”) and Aurena Laboratories Holding AB (“Aurena”), (the “Transaction”).
As communicated in the press release on 14 December 2022, the final transfer of shares to Cerbios and Aurena is conditional on Lipidor’s General Meeting approving the Transaction. Following the EGM’s resolution, the Transaction will be made.
The Transaction approved by the EGM refers to a transfer of 529 shares in Emollivet (the “Emollivet shares”), corresponding to a total of 22 percent of the shares and votes Emollivet to Cerbios and Aurena at a purchase price of a total of SEK 3,856,410. Of these shares, Cerbios shall receive 412 Emollivet shares at a purchase price of SEK 3,003,480 and Aurena shall receive 117 Emollivet shares at a purchase price of SEK 852,930. Lipidor has engaged an independent advisor, AG Equity Research AB, which has valued Emollivet at a total of approximately MSEK 15.4 – 21.7. Based on the valuation report, the parties have agreed on a price per share of SEK 7,290, which means that Emollivet is valued at a total of approximately MSEK 17.5. Access to the Emollivet shares is expected to take place in January 2023. The consideration will consist of cash.
Neither Cerbios nor Aurena, or other companies in their groups, were represented on the EGM.